Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06782490 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
A Phase 2 study of Multiple Sclerosis Spasticity, sponsored by Celgene.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT06782490: Recruiting Phase 2 study of Multiple Sclerosis Spasticity, sponsored by Celgene.
NCT06782490 is a Phase 2 study of Multiple Sclerosis Spasticity that is actively recruiting participants, run by Celgene. The registered enrollment target is 200 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06782490, a Phase 2 study of Multiple Sclerosis Spasticity, is actively recruiting participants, sponsored by Celgene.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BMS-986368
Study Locations (20)
Ohio
- University of Cincinnati Medical Center - Cincinnati
- Local Institution - 0039 - Columbus
- Local Institution - 0069 - Columbus
Victoria
- Box Hill Hospital - Box Hill
- Austin Health - Heidelberg
- The Royal Melbourne Hospital - Parkville
Florida
- Aqualane Clinical Research - Naples
- USF Health - Tampa
New South Wales
- John Hunter Hospital - Newcastle
- University of Sydney - Brain and Mind Research Institute (BMRI) - Sydney
Alabama
- Local Institution - 0033 - Birmingham
Arizona
- Perseverance Research Center,LLC - Scottsdale
Colorado
- Local Institution - 0017 - Aurora
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-06-05 |
| Est. Completion | 2027-06-09 |
| Phase | Phase 2 |
What NCT06782490 shows while recruiting
NCT06782490 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher).
The record links to 1 condition, with Multiple Sclerosis Spasticity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06782490 names 20 study sites across 14 states, led by Ohio, Victoria, Florida.
Frequently Asked Questions
What is clinical trial NCT06782490 about?
NCT06782490 is a clinical study titled "A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity". The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity
What is the current status of trial NCT06782490?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-06-05. Estimated completion is 2027-06-09.
What conditions does trial NCT06782490 study?
This clinical trial studies the following conditions: Multiple Sclerosis Spasticity.
What interventions are being tested in trial NCT06782490?
The interventions under investigation include: Placebo (DRUG), BMS-986368 (DRUG).
Who is sponsoring clinical trial NCT06782490?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06782490 being conducted?
This trial has 20 study locations across Alabama, Arizona, Colorado, Florida, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06782490's enrollment target sits among peer trials
200 304th of 2000 higher than 1,652 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI